Recent advances in the treatment of headaches

Current Opinion in Anaesthesiology

Volumn 18, Issue 5, 2005, Pages 563-568

  Evers, Stefan ^a   Frese, Achim ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Cluster headache; Headache classification; Migraine; Tension type headache

Indexed keywords

ALMOTRIPTAN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CANDESARTAN; ELETRIPTAN; ERGOTAMINE TARTRATE; ETIRACETAM; INDOMETACIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LITHIUM; METOCLOPRAMIDE; MIRTAZAPINE; MONTELUKAST; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OLCEGEPANT; PROPRANOLOL; RIZATRIPTAN; SEROTONIN ANTAGONIST; STEROID; SUMATRIPTAN; TANACETUM PARTHENIUM EXTRACT; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZOLMITRIPTAN;

CLINICAL TRIAL; CLUSTER HEADACHE; DIZZINESS; HEADACHE; HEART ATRIUM SEPTUM DEFECT; HUMAN; MIGRAINE; NERVE STIMULATION; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SIDE EFFECT; TENSION HEADACHE; WEIGHT REDUCTION;

EID: 26244437461     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000183105.73931.6b     Document Type: Review

References (78)

1. Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 2nd ed. Cephalalgia 2004; 24 (Suppl. 1):1-160.
2. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005; 45:156-162.
3. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia. Ann Neurol 2004; 55:19-26. An excellent experimental study showing that allodynia is the major predictor for the response to triptans. This study transfers findings in animal studies to humans.
4. Burstein R, Jakubowski M. Analgesic triptan action in animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol 2004; 55:27-36. An experimental animal study demonstrating that triptans have an influence on the development of central sensitization.
5. Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine. Headache 2003; 43:1075-1079.
6. Mathew N, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 2004; 344:669-673. This clinical trial shows that early treatment with a triptan is more effective than late treatment (when the pain is moderate or severe).
7. Olesen J, Diener HC, Schoenen J, Hettiarachchi J. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol 2004; 11:671-677. Further evidence that triptans are not effective when given during the aura.
8. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology 1994; 44:1587-1592.
9. Dowson A. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Eur Neurol 1996; 36 (Suppl. 2):28-31.
10. Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003; 43:729-733.
11. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62:563-568. A large epidemiological study from the USA on the prevalence of vascular events in patients taking triptans. This study demonstrates that triptans are safe and without a significant incidence of cardiovascular or cerebrovascular events.
12. Mathew N, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43:214-222.
13. Steiner T, Diener HC, MacGregor E, et al. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003; 23:942-952.
14. Garcia-Ramos G, MacGregor EA, Milliard B, et al. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003; 23:869-876.
15. Färkkilä M, Olesen J, Dahlöf C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003; 23:463-471.
16. Chia Y, Lim S, Wang S, et al. Efficacy of eletriptan for the treatment of migraine with persistent poor response to nonsteroidal anti-inflammatory drugs. Headache 2003; 43:984-990.
17. Christie S, Göbel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg and ergotamine/caffeine in migraine. Eur Neurol 2002; 49:20-29.
18. Kolodny A, Polis A, Battisti WP, et al. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia 2004; 24:540-546. This study shows that rizatriptan 10 mg is more efficacious than sumatriptan 50 mg.
19. Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Eur Neurol 2005; 53 (Suppl. 1):41-48.
20. Ahonen K, Hämäläinen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology 2004; 62:883-887. This study confirms previous studies that sumatriptan nasal spray is efficacious in the treatment of childhood migraine attacks.
21. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin-gene-related peptide receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. N Engl J Med 2004; 350:1104-1110. A new mechanism, antagonism of CGRP, is efficacious and safe in the treatment of acute migraine attacks. This is the first positive clinical study after the development of the triptans with a new mechanism. It is based on previous findings on the pathophysiology of migraine.
22. Stillman M, Zajac D, Rybicki L. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache 2004; 44:65-69.
23. Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004; 329:1369-1373. Intravenous metoclopramide alone and in combination with analgesics has a positive effect on migraine symptoms.
24. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005; 64:463-468. Intravenous metoclopramide has a specific analgesic effect in migraine treatment and has nearly the same potency to treat migraine attacks as sumatriptan.
25. Goadsby PJ. New targets in the acute treatment of headache. Curr Opin Neurol 2005; 18:283-288. An excellent review on the new drugs currently under evaluation for migraine treatment.
26. Silberstein SD, Neto W, Schmitt J, et al. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61:490-495. One of the large studies showing that topiramate is effective in the prophylaxis of migraine.
27. Diener HC, Tfelt-Hansen P, Dahlöf C, et al. Topiramate in migraine prophylaxis results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251:943-950. Another study showing that topiramate is effective in the prophylaxis of migraine. In addition, topiramate is equivalent to propranolol.
28. Brandes J, Saper J, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291:965-973. One of the large studies showing that topiramate is effective in the prophylaxis of migraine.
29. Miller GS. Efficacy and safety of levetiracetam in pediatric migraine. Headache 2004; 44:238-243.
30. Gallai V, Alberto A, Rossi C, et al. An open-label study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine. J Headache Pain 2003; 4:92-96.
31. Tronvik E, Stovner L, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289:65-69.
32. Brandes JL, Visser WH, Farmer MV, et al. Montelukast for migraine prophylaxis: a randomized, double-blind, placebo-controlled study. Headache 2004; 44:581-586. Montelukast, a completely new mechanism in migraine prevention, is clinically not efficacious.
33. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004; (1):CD002286.
34. Diener HC, Rahlfs VW, Danesch U. The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. Eur Neurol 2004; 51:89-97.
35. Lipton RB, Göbel H, Einhäupl KM, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004; 63:2240-2244. A large trial demonstrating significant efficacy of the phytotherapeutic drug petasites in migraine prophylaxis.
36. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine - a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24:838-843. Botulinum toxin was not superior to placebo in migraine prophylaxis.
37. Evers S. Botulinum toxin and the management of chronic headaches. Curr Opin Otolaryngol Head Neck Surg 2004; 12:197-203.
38. Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 2004; 24:60-65. Botulinum toxin was not superior to placebo in reducing headache frequency. Only some secondary parameters were in favour of botulinum toxin.
39. Dodick DW, Mauskop A, Elkind AH, et al. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45:315-324. The subanalysis of a trial, which could not prove the superiority of botulinum toxin compared with placebo, showing that patients without other prophylactic drugs might benefit from botulinum toxin.
40. Wilmshurst PT, Pearson MJ, Nightingale S, et al. Inheritance of persistent foramen ovale and atrial septal defects and the relation to familial migraine with aura. Heart 2004; 90:1315-1320. The increased prevalence of some heart failures in migraine patients might follow a dominant inheritance pattern.
41. Beda RD, Gill EA Jr. Patent foramen ovale: does it play a role in the pathophysiology of migraine headache? Cardiol Clin 2005; 23:91-96. This clinical study suggests that closure of the PFO might lead to a decrease in migraine prevalence and frequency.
42. Morandi E, Anzola GP, Angeli S, et al. Transcatheter closure of patent foramen ovale: a new migraine treatment? J Intervent Cardiol 2003; 16:39-42.
43. Post MC, Thijs V, Herroelen L, Budts WI. Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine. Neurology 2004; 62:1439-1440. Another study supporting the idea that closure of the PFO might have a positive impact on migraine.
44. Schwerzmann M, Wiher S, Nedeltchev K, et al. Percutaneous closure of patent foramen ovale reduces the frequency of migraine attacks. Neurology 2004; 62:1399-1401. Another study supporting the idea that closure of the PFO might have a positive impact on migraine.
45. Reisman M, Christofferson RD, Jesurum J, et al. Migraine headache relief after transcatheter closure of patent foramen ovale. J Am Coll Cardiol 2005; 45:493-495. Another study supporting the idea that closure of the PFO might have a positive impact on migraine.
46. Azarbal B, Tobis J, Suh W, et al. Association of interatrial shunts and migraine headaches: impact of transcatheter closure. J Am Coll Cardiol 2005; 45:489-492. Another study supporting the idea that closure of the PFO might have a positive impact on migraine.
47. Wilmshurst PT, Nightingale S, Walsh KP, Morrison WL. Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet 2000; 356:1648-1651.
48. Mortelmans K, Post M, Thijs V, et al. The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 2005; 26:1533-1537. This study showed an effect of PFO closure on migraine frequency only in a subgroup of patients.
49. Matharu M, Bartsch T, Ward N, et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 2003; 127:220-230.
50. Linde M, Fjell A, Carlsson J, Dahlöf C. Role of the needling per se in acupuncture as prophylaxis for menstrually related migraine: a randomized placebo-controlled study. Cephalalgia 2005; 25:41-47. Verum acupuncture is equivalent to sham acupuncture in reducing migraine frequency.
51. Linde K, Streng A, Jürgens S, et al. Acupuncture for patients with migraine: a randomized controlled trial. JAMA 2005; 293:2118-2125. An excellent study showing that verum and sham acupuncture are no different in migraine prophylaxis but are superior to a waiting list with standard treatment.
52. Vickers AJ, Rees RW, Zollman CE, et al. Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ 2004; 328:744.
53. Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry 1996; 61:285-290.
54. Holroyd K, Labus J, O'Donnell F, et al. Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation. Headache 2003; 43:999-1004.
55. Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain 2004; 108:108-114. An excellent experimental study showing that the mechanisms of amitriptyline in preventing tension-type headache do not depend primarily on the antidepressive mechanisms.
56. Bendtsen L, Jensen R. Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. Neurology 2004; 62:1 706-1 711. An interesting study because it shows the efficacy of a non-tricyclic antidepressant in tension-type headache.
57. Schulte-Mattler W, Krack P, BoNTTH study group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004; 109:110-114. Botulinum toxin was not superior to placebo in the prophylaxis of chronic tension-type headache.
58. Padberg M, de Bruijn SF, de Haan RJ, Tavy DL. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004; 24:675-680. Botulinum toxin was not superior to placebo in the prophylaxis of chronic tension-type headache.
59. Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study. Cephalalgia 2004; 24:29-36. Physiotherapy is more effective than standard treatment and waiting list in tension-type headache. An interesting study also from a methodoligical point of view.
60. Vliet JA, Bahra A, Martin V, et al. Intranasal sumatriptan in cluster headache: randomized, placebo-controlled double-blind study. Neurology 2003; 60:630-633.
61. Bahra A, Gawel MJ, Hardebo JE, et al. Oral zolmitriptan is effective in the acute treatment of cluster headache. Neurology 2000; 54:1832-1839.
62. Mulder LJ, Spierings EL. Naratriptan in the preventive treatment of custer headache. Cephalalgia 2002; 22:815-817.
63. Lainez M, Pascual J, Pascual A, et al. Topiramate in the prophylactic treatment of cluster headache. Headache 2003; 43:784-789.
64. Förderreuther S, Mayer M, Straube A. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 2002; 22:186-189.
65. Leone M, Dodick D, Rigamonti A, et al. Topiramate in cluster headache prophylaxis: an open trial. Cephalalgia 2003; 23:1001-1002.
66. Leone M, Franzini A, Bussone G. Stereotactic stimulation of posterior hypothalamic gray matter in a patient with intractable cluster headache. N Engl J Med 2001; 345:1428-1429.
67. Leone M, Franzini A, Broggi G, et al. Long-term follow-up of bilateral hypothalamic stimulation for intractable cluster headache. Brain 2004; 127:2259-2264. An excellent study and the largest case series on the treatment of refractory cluster headache with hypothalamic stimulation. Also includes some neuroimaging data.
68. Franzini A, Ferroli P, Leone M, et al. Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headache: first reported series. Neurosurgery 2003; 52:1095-1101.
69. Schoenen J, Di Clemente L, Vandenheede M, et al. Hypothalamic stimulation in chronic cluster headache: a pilot study of efficacy and mode of action. Brain 2005; 128:940-947. Another case series on the efficacy of hypothalamic stimulation in refractory cluster headache. Unfortunately also reporting one death after implantation of the electrodes.
70. Matharu MS, Cohen AS, Boes CJ, Goadsby PJ. Short-lasting unilateral neuralgiform headache with conjunctival injection and tearing syndrome: a review. Curr Pain Headache Rep 2003; 7:308-318.
71. Evers S, Frese A, May A, et al. Treatment of rare other primary headaches - recommendations of the German Migraine and Headache Society [in German]. Nervenheilkunde 2005; 24:217-226.
72. Franca MC, Costa ALC, Maciel JA. Gabapentin-responsive idiopathic stabbing headache. Cephalalgia 2004; 24:993-996.
73. Rozen TD. Melatonin as treatment for idiopathic stabbing headache. Neurology 2003; 61:865-866.
74. Wang SJ, Fuh JL, Lu SR. Benign cough headache is responsive to acetazolamide. Neurology 2000; 55:149-150.
75. Bahra A, Goadsby PJ. Cough headache responsive to methysergide. Cephalalgia 1998; 18:495-496.
76. Frese A, Eikermann A, Frese K, et al. Headache associated with sexual activity. Demography, clinical features, and comorbidity. Neurology 2003; 61:796-800.
77. Evers S, Goadsby PJ. Hypnic headache. Clinical features, pathophysiology, and treatment. Neurology 2003; 60:905-910.
78. Lu SR, Liao YC, Fuh JL, et al. Nimodipine for treatment of primary thunderclap headache. Neurology 2004; 62:1414-1416.